Lumexa Imaging Holdings, Inc. Common Stock (LMRI) Stock

Lumexa Imaging Holdings, Inc. Common Stock (LMRI) is a Healthcare stock trading at $12.06 (as of 2026-08-25), with a market capitalization of $1.13B and a trailing P/E of 656.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company provides outpatient medical imaging services, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) services, as well as X-ray, ultrasound, and mammography diagnostic and screening imaging services. The company was founded in 2018 and is based in Raleigh, North Carolina.

Understand Lumexa Imaging Holdings, Inc. Common Stock: how it makes money

Lumexa Imaging operates outpatient diagnostic imaging centers in the US, offering MRI, CT, PET, mammography, and ultrasound to referring physicians and insurers. The model is capital-intensive because the company owns the equipment and facilities, so profitability depends on keeping expensive machines busy.

Each center's profit is a function of scanner utilization and insurance reimbursement rates; the moat is geographic convenience and primary-care referral relationships, not proprietary technology or data.

Business quality (Weak): The company earns a 7.7% operating margin on a small revenue base, generates a 1% return on equity, and trades at a P/E roughly 26x the industry median. On current fundamentals the valuation gap is very hard to justify.

Valuation: At 656× earnings, LMRI trades 2490% above the Healthcare Services average (25×).

Bull case

  • Profitable and growing: Quarterly revenue of $300 million grew 3% YoY while the company maintained a 7.7% operating margin, confirming the imaging-center model clears its costs and is expanding at a steady pace.

Bear case

  • Valuation implausible on current data: The stock trades at a P/E of 656.4x, approximately 2,490% above the 25.3x Healthcare Services industry median. A multiple that large would require sustained hyper-growth to attract at all, and the 3% revenue growth rate does not point in that direction.
  • Capital returns near zero: Return on equity is 1.0%, meaning each dollar of shareholder capital generates roughly a cent of profit per period. That signal says the capital tied up in scanners, leases, and clinical staff is not yet compounding at a rate consistent with the price the market is paying.
Valuation — source: SEC EDGAR (first-party)
Price$12.06
Market Cap$1.13B
P/E Ratio656.4
EV / EBITDA65.0
Price / Book1.88
Price / Sales4.46
FCF Yield-0.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$948.87M
Net Margin-9.9%
Return on Equity0.3%
Debt / Equity1.38
Current Ratio1.40
Revenue Growth (YoY)3.1%
EPS Growth (YoY)-118.2%
FCF Growth (YoY)-84.1%
Valuation vs Sector & Industry
Stock P/E656.4
Sector P/E (Healthcare)21.9
Industry P/E (Healthcare Services)25.4
vs Sector2892.3%
vs Industry2483.1%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderALLIANCEBERNSTEIN L.P. ($55.14M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryHealthcare Services
CEOCaitlin Zulla
CountryUS
IPO Date2025-12-11

Related Companies (Healthcare Services; 8 comparable companies)

  • Guardant Health, Inc. (GH)
  • Caris Life Sciences, Inc. (CAI)
  • Veracyte, Inc. (VCYT)
  • RadNet, Inc. (RDNT)
  • Natera, Inc. (NTRA)
  • CareDx, Inc (CDNA)
  • Castle Biosciences, Inc. (CSTL)
  • Fortrea Holdings Inc. (FTRE)
LMRI earnings history · LMRI institutional & insider holders · LMRI KPIs & operating metrics · LMRI financials · LMRI investor presentations & press releases · LMRI SEC filings · LMRI peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-25.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.